COMMUNIQUÉ DE PRESSE

Tous les communiqués de presse

Page 1 sur 4.

Veracyte Completes Acquisition of HalioDx

Fuels growth by enabling IVD test development and manufacturing for nCounter diagnostic platform

Expands scientific...

 Lire la suite

HalioDx and Veracyte set proposed acquisition terms

French version available (pdf)

 Lire la suite

Immunoscore® is now available in Rectal Cancer for expert clinical centers through an Innovation Access Program

  • Immunoscore® heads up to become the standard precision tool for the “Watch and Wait” strategy in locally advanced...

 Lire la suite

IMMUNOSCORE® in Colon Cancer

HalioDx Partners with DASA, the Largest Diagnostics Provider in Latin America, to make Immunoscore® available in Brazil

HalioDx SAS, the immuno-oncology diagnostic company pioneering the immunological diagnosis of cancers, today announced...

 Lire la suite

Distributors

Expanding Immunoscore® clinical utility on 3000+ stage III colon cancer patients

HalioDx SAS, the immuno-oncology diagnostic company pioneering the immunological diagnosis of cancers, today announced...

 Lire la suite

IMMUNOSCORE® in Colon Cancer

New data reinforce Immunoscore® clinical utility in localized Colon Cancer

  • Changes in patterns of oncology care with the incorporation of immune response in a study of Stage II colon cancer...
 Lire la suite

Paltown Development Foundation and HalioDx Team Up for Colorectal Cancer Testing Center

COLONTOWN University Launches Secure Platform for Colorectal Cancer Patients

HalioDx SAS, the immuno-oncology...

 Lire la suite

IMMUNOSCORE® in Colon Cancer

Mr Gilles Bloch, Président Directeur Général de l’Inserm, remet l’insigne de Chevalier de la Légion d’honneur à Jérôme Galon

HalioDx SAS, la société de diagnostic en immuno-oncologie, a annoncé aujourd'hui que son fondateur scientifique,...

 Lire la suite

Jérôme Galon has been awarded the French the Legion of Honor, or "Legion d'Honneur", received today from Gilles Bloch, Chairman and Chief Executive Officer of Inserm

Lire la suite

HalioDx contribution to precision medicine at ESMO 2020

HalioDx SAS, the immuno-oncology diagnostic company, today announced that, at the European Society of Medical OncologyV...

 Lire la suite

IMMUNOSCORE® IC in NSCLC

Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer

HalioDx SAS, the immuno-oncology diagnostic company, today announced that it has entered into a Collaboration Agreement...

 Lire la suite

IMMUNOSCORE® in Colon Cancer

Immunoscore® included in ESMO Clinical Practice Guidelines 2020

HalioDx SAS, the immuno-oncology diagnostic company, today announced that Immunoscore® has been included in the 2020...

 Lire la suite

IMMUNOSCORE® in Colon Cancer

HalioDx strengthens its Management Team

  • Stephane Debono, EVP, Diagnostics BU and CEO of HalioDx Inc., is appointed Deputy CEO
  • Philippe Mourere joins the...
 Lire la suite

New evidence from 2 pivotal studies reinforces clinical value of Immunoscore® In Colon Cancer

  • Two large Immunoscore® studies from Phase III trials published in JNCI Cancer Spectrum & Annals of Oncology
  • Consisten...
 Lire la suite

IMMUNOSCORE® in Colon Cancer

HalioDx to Characterize the Immune Contexture of Patients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial

HalioDx’s immunoscoring technologies  to characterize patients treated with ImCheck’s investigational first-in-class...

 Lire la suite

COVID-19 Business continuity plan

Considering the recent evolution of the COVID-19 situation, HalioDx has actioned a business continuity plan aimed at...

 Lire la suite

Immune response is now part of the Essential and Desirable Diagnostic Criteria for Colorectal Cancers in the 5th edition of the WHO Classification of Tumours

Lire la suite

IMMUNOSCORE® in Colon Cancer

A new milestone for Immunoscore® in the UK

Five major private medical insurances in the UK cover Immunoscore® test for all their patients with localised colon...

 Lire la suite

OSE Immunotherapeutics and HalioDx Collaborate to Perform Immune Biomarker Exploratory Work during Atalante 1 Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer

OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), a clinical-stage biotechnology company focused on developing...

 Lire la suite

HalioDx and Kite, a Gilead company, to extend strategic collaboration beyond Lymphoma

Kite to Leverage HalioDx’s Immunoscore® Solutions to Understand Tumor Microenvironment and Guide Cancer Cell Therapies...

 Lire la suite

Page 1 sur 4.